Chang Hsin-An, Lu Ru-Band, Lin Wei-Wen, Chang Chuan-Chia, Chen Chih-Lun, Shy Mee-Jen, Huang San-Yuan
1Department of Psychiatry, Tri-Service General Hospital, Taipei, Taiwan.
2Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Acta Neuropsychiatr. 2007 Dec;19(6):344-50. doi: 10.1111/j.1601-5215.2007.00214.x.
The Ser9Gly polymorphism in dopamine D3 receptor gene (DRD3) was considered an important factor in the pathogenesis of schizophrenia. Allele and genotype frequencies of this polymorphism were studied in different ethnic groups of schizophrenic patients. However, the results have been inconclusive.
To determine whether the DRD3 Ser9Gly polymorphism is associated with schizophrenia or influences its psychopathological symptoms in Han Chinese population.
We recruited 256 schizophrenic patients and 285 normal controls matched for gender, age and ethnicity. Pretreatment psychotic symptoms were evaluated with the Positive and Negative Symptom Scale (PANSS) in 128 acutely exacerbated schizophrenic in-patients. Genotyping of Ser9Gly polymorphism was performed with a polymerase chain reaction restriction fragment length polymorphism method and reconfirmed by a direct sequencing technique.
No significant difference was found between either patients with schizophrenia or with more homogeneous schizophrenic subgroups and healthy controls in genotype distributions and allele frequencies for the DRD3 Ser9Gly polymorphism. Similarly, DRD3 Ser9Gly genotype differences failed to reach significance in PANSS global, positive, negative and general symptoms scores. There is a trend (P = 0.064) towards higher PANSS positive symptoms scores in subjects carrying the Gly/Gly genotype.
This study does not support the role of DRD3 Ser9Gly polymorphism in increasing genetic risk for schizophrenia in Han Chinese population. Still, there is a possibility that the DRD3 Ser9Gly variant may reflect genetic variation of severity of positive symptoms in acutely exacerbated schizophrenia. Further studies are warranted to investigate the effect of the DRD3 Ser9Gly polymorphism in relation to longer time course of schizophrenia, including treatment response to antipsychotics.
多巴胺D3受体基因(DRD3)中的Ser9Gly多态性被认为是精神分裂症发病机制中的一个重要因素。已对不同种族的精神分裂症患者群体中该多态性的等位基因和基因型频率进行了研究。然而,结果尚无定论。
确定DRD3 Ser9Gly多态性是否与中国汉族人群的精神分裂症相关或影响其精神病理症状。
我们招募了256例精神分裂症患者和285名在性别、年龄和种族上相匹配的正常对照。对128例急性加重的精神分裂症住院患者,采用阳性和阴性症状量表(PANSS)评估治疗前的精神病症状。采用聚合酶链反应-限制性片段长度多态性方法对Ser9Gly多态性进行基因分型,并通过直接测序技术进行再次确认。
在DRD3 Ser9Gly多态性的基因型分布和等位基因频率方面,精神分裂症患者或更同质的精神分裂症亚组与健康对照之间均未发现显著差异。同样,DRD3 Ser9Gly基因型差异在PANSS总分、阳性、阴性及一般症状评分中也未达到显著水平。携带Gly/Gly基因型的受试者PANSS阳性症状评分有升高趋势(P = 0.064)。
本研究不支持DRD3 Ser9Gly多态性在增加中国汉族人群精神分裂症遗传风险中的作用。不过,DRD3 Ser9Gly变异仍有可能反映急性加重型精神分裂症阳性症状严重程度的遗传变异。有必要进一步研究DRD3 Ser9Gly多态性在精神分裂症较长病程中的作用,包括对抗精神病药物治疗反应的影响。